These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 17653802

  • 1. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R, Ellis LM.
    Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
    [Abstract] [Full Text] [Related]

  • 2. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.
    Cancer Res; 2005 Sep 01; 65(17):7775-81. PubMed ID: 16140945
    [Abstract] [Full Text] [Related]

  • 3. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 4. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.
    Cancer; 2000 Aug 01; 89(3):488-99. PubMed ID: 10931447
    [Abstract] [Full Text] [Related]

  • 5. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.
    Cancer Res; 2003 Dec 15; 63(24):8912-21. PubMed ID: 14695208
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4291-9. PubMed ID: 17634559
    [Abstract] [Full Text] [Related]

  • 7. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
    Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA.
    Cancer Immunol Immunother; 2007 Mar 15; 56(3):343-57. PubMed ID: 16832681
    [Abstract] [Full Text] [Related]

  • 8. Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells.
    Zhang Y, Zhang Y.
    Cancer Invest; 2008 Mar 15; 26(3):230-6. PubMed ID: 18317963
    [Abstract] [Full Text] [Related]

  • 9. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 15; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 10. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.
    Clin Cancer Res; 2006 Nov 15; 12(22):6772-80. PubMed ID: 17121898
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD.
    Clin Cancer Res; 2005 Mar 01; 11(5):2063-73. PubMed ID: 15756033
    [Abstract] [Full Text] [Related]

  • 12. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094
    [Abstract] [Full Text] [Related]

  • 13. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R.
    Cancer Res; 2003 Aug 15; 63(16):5073-83. PubMed ID: 12941837
    [Abstract] [Full Text] [Related]

  • 14. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.
    Clin Cancer Res; 2008 Aug 15; 14(16):5124-30. PubMed ID: 18698030
    [Abstract] [Full Text] [Related]

  • 15. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H.
    Int J Oncol; 2008 Nov 15; 33(5):1107-13. PubMed ID: 18949375
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1558-70. PubMed ID: 17077358
    [Abstract] [Full Text] [Related]

  • 18. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers.
    Miyamoto S, Nakamura M, Shitara K, Nakamura K, Ohki Y, Ishii G, Goya M, Kodama K, Sangai T, Maeda H, Shi-Chuang Z, Chiba T, Ochiai A.
    Clin Cancer Res; 2005 May 01; 11(9):3494-502. PubMed ID: 15867252
    [Abstract] [Full Text] [Related]

  • 19. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
    Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ, Kandel JJ.
    J Pediatr Surg; 2001 Aug 01; 36(8):1177-81. PubMed ID: 11479851
    [Abstract] [Full Text] [Related]

  • 20. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer.
    Reinmuth N, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, Bucana CD, Radinsky R, Ellis LM.
    Clin Cancer Res; 2002 Oct 01; 8(10):3259-69. PubMed ID: 12374697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.